TAZORAC (tazarotene) by Almirall is form, the carboxylic acid of tazarotene, by deesterification. Approved for retinoid [epc]. First approved in 2000.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
TAZORAC (tazarotene) is a topical retinoid cream approved in 2000 for the treatment of acne and psoriasis. It works by decreasing cohesiveness of follicular epithelial cells and stimulating mitotic activity to increase cell turnover. The drug is administered topically and represents a first-generation retinoid in dermatology.
Product is approaching loss of exclusivity with modest Part D spending of $2M; commercial teams will transition from growth management to lifecycle extension and generic defense strategies.
form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARɣ, but shows relative selectivity for RARβ, and RARɣ and may modify gene expression. The clinical significance of these findings…
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
Worked on TAZORAC at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TAZORAC offers limited growth opportunity given the product's LOE-approaching status and modest Part D spending of $2M; career progression will depend on execution of defensive strategies against competitive inroads from DUOBRII and ARAZLO rather than revenue expansion. This role suits professionals seeking experience in mature-product optimization, generic defense, and lifecycle management in specialty dermatology.